Long-Term Study Finds Early TAVR Health Status Gains Equalize With Surgery at Seven Years

Key facts

The long-term study examined patients with severe aortic stenosis who were classified as low risk for open surgery and randomized to receive either transcatheter aortic valve replacement (TAVR) or surgical aortic valve replacement (SAVR). Researchers systematically tracked health status metrics and patient-reported outcomes over a seven-year follow-up period.

During the initial post-procedural phase—spanning the weeks and months immediately following intervention—patients who received TAVR demonstrated a pronounced advantage in health status and physical recovery relative to those undergoing traditional open-heart surgery. This early gap was driven primarily by the less invasive nature of the transcatheter procedure, which avoids median sternotomy, cardiac arrest, and cardiopulmonary bypass, thereby allowing patients to mobilize more quickly and return to baseline activities faster.

However, as the evaluation extended through seven years of follow-up, the initial statistical and clinical divergence in health status narrowed between the two cohorts. According to reporting by The Cardiology Advisor, the long-term data indicates that while TAVR confers an early advantage in post-procedural recovery speed, the overall long-term health status trajectories of TAVR and SAVR patients converge over time, yielding comparable quality-of-life profiles at seven years.

Why it matters

The expansion of transcatheter aortic valve replacement into low-risk patient populations represents one of the most substantial shifts in cardiovascular medicine over the past decade. Unlike high-risk or elderly patients evaluated in early TAVR trials, low-risk individuals are generally younger, possess fewer medical comorbidities, and face decades of remaining life expectancy. Consequently, treatment selection in low-risk patients requires balancing immediate recovery benefits against long-term outcomes, valve durability, and potential future interventions.

The finding that initial health status advantages associated with TAVR taper off over a seven-year timeframe carries practical implications for structural heart teams and patient counseling. When patients evaluate procedural choices, the prospect of a faster recovery and shorter hospital stay often serves as a primary driver toward selecting a catheter-based approach. While the new data confirms that TAVR delivers on this early promise, it underscores that over the long term, open-heart surgery provides an equivalent quality of life and functional state.

From a health economics perspective, these findings shape how health systems, insurers, and clinical decision-makers evaluate the cost-effectiveness of structural valve interventions. Surgical valve replacement typically involves higher upfront hospital costs due to intensive care unit stays and extended inpatient rehabilitation, whereas TAVR involves higher initial device costs. If long-term patient health status and functional capacity converge, economic analyses will increasingly depend on procedural complication rates, structural valve durability, and the long-term necessity of secondary re-interventions rather than sustained health status differences.

Aortic stenosis is a mechanical obstruction of the left ventricular outflow tract caused by progressive calcification and narrowing of the aortic valve leaflets. Left untreated, severe symptomatic aortic stenosis carries a poor prognosis, leading to heart failure, syncope, and cardiac death. For decades, surgical aortic valve replacement (SAVR) stood as the definitive standard of care. Open-heart surgery involves opening the chest via median sternotomy, stopping the heart, placing the patient on cardiopulmonary bypass, excising the diseased native valve, and sewing in a mechanical or bioprosthetic valve.

In the late 2000s, transcatheter aortic valve replacement (TAVR) emerged as a disruptive alternative. TAVR allows interventional cardiologists to deliver a collapsed bioprosthetic valve through a catheter—typically inserted via the femoral artery in the groin—and expand it within the native diseased valve under fluoroscopic guidance. Because TAVR avoids open chest surgery and cardiac arrest, early clinical trials focused on patients deemed inoperable or at extreme surgical mortality risk.

Following consistent demonstration of safety and efficacy in high-risk patients, clinical trials expanded to intermediate-risk populations, and eventually to low-risk patients. Major randomized trials, such as the PARTNER 3 trial testing balloon-expandable valves and the Evolut Low Risk trial testing self-expanding valves, established that TAVR was non-inferior—and in some early composite endpoints, superior—to SAVR in low-risk cohorts, leading regulatory agencies to approve TAVR for low-risk patients in late 2019.

Despite widespread clinical adoption, long-term questions remain regarding bioprosthetic valve durability. Surgical bioprosthetic valves have extensive historical registries demonstrating structural durability for 10 to 15 years or longer. In contrast, long-term transcatheter valve durability in younger, low-risk populations remains an area of active study, making multi-year follow-up comparisons between TAVR and SAVR essential to contemporary cardiology practice.

Reaction

Cardiovascular specialists and multidisciplinary heart teams are expected to review these multi-year outcomes to refine clinical decision-making algorithms and patient consent discussions. In modern practice, treatment decisions for aortic valve disease are conducted by heart teams composed of interventional cardiologists, cardiothoracic surgeons, clinical cardiologists, and imaging specialists.

While formal clinical guidelines from major professional bodies—such as the American College of Cardiology (ACC), the American Heart Association (AHA), and the European Society of Cardiology (ESC)—currently endorse both TAVR and SAVR as reasonable options for low-risk patients based on patient age and anatomical considerations, clinicians are expected to incorporate seven-year health status data into patient-centered care models. Expert commentary within the cardiology community generally emphasizes that while TAVR remains highly appealing for patients prioritizing immediate post-procedural recovery, long-term equivalency in health status highlights the ongoing role and durability of surgical valve replacement in younger, low-risk candidates.

What we don't know yet

Several key details remain unclarified in the initial reporting summary from The Cardiology Advisor:

What to watch

Looking ahead, several key clinical developments and milestones will provide further clarity on the relative long-term efficacy of TAVR versus SAVR in low-risk patients:

This report is based on original clinical reporting published by The Cardiology Advisor on September 4, 2026.